Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2026
Reporting Period: Single event date (August 24, 2026)
This filing serves as a Regulation FD disclosure regarding a significant regulatory milestone for the company's Helix Transendocardial Delivery Catheter.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific regulatory event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Milestone: On August 24, 2026, the U.S. Food and Drug Administration (FDA) confirmed the Helix Transendocardial Delivery Catheter Meeting Minutes. This confirmation supports the company's follow-on De Novo pre-submission for approval.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (attached as Exhibit 99.1) announcing the FDA confirmation. The filing explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: The filing does not detail specific risks or contingencies beyond the standard regulatory process implied by the pre-submission status.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed context on the FDA meeting minutes.
- Confirm the specific timeline and requirements for the "follow-on De Novo pre-submission" mentioned in the filing.
- Review subsequent filings for any updates on the approval status of the Helix Transendocardial Delivery Catheter.
- Note that this 8-K does not contain financial data; refer to the most recent 10-Q or 10-K for financial health metrics.